Pentoxifylline for Cocaine Use Disorder
Placebo
+ Cocaine (IV)
+ Pentoxifylline
Basic Science Study
Summary
Study start date: November 10, 2025
Actual date on which the first participant was enrolled.This study aims to explore how a medication called pentoxifylline might affect people who use cocaine. Cocaine use disorder is a condition where individuals struggle to control their cocaine use, leading to various health and social problems. Researchers are interested in understanding if pentoxifylline, which is known to target inflammation in the body, can alter the effects of cocaine. This could potentially lead to new ways to help those with cocaine use disorder by reducing harmful effects or cravings associated with cocaine use. Participants in this study will receive pentoxifylline and then be observed in a controlled environment to see how it influences their response to cocaine. This involves monitoring various aspects, such as the body's reaction and any changes in behavior or cravings. By examining these responses, researchers hope to gather valuable data on the interaction between pentoxifylline and cocaine, paving the way for future treatments. The study is conducted carefully to ensure participants' safety while collecting essential information.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.30 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Basic Science Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 55 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Criteria
Inclusion Criteria: 1. able to speak/read English, 2. not seeking treatment for drug use at the time of the study, 3. female or male between the ages of 18 and 55 years, 4. recent smoked or intravenous cocaine use verified by benzoylecgonine positive urine, as well as fulfillment of DSM-5 diagnostic criteria for CUD, 5. judged to be medically and psychiatrically healthy by study physicians other than the diagnosis for CUD at the time of screening, 6. ECG, read by a cardiologist, within normal limits, 7. females using an effective form of birth control and not pregnant or breastfeeding and 8) no known contraindications or allergies to pentoxifylline. Exclusion Criteria: 1. unable to speak/read English, 2. seeking treatment for drug use, 3. under 18 years or over 55 years, 4. no recent smoked or intravenous cocaine use as indicated by benzoylecgonine negative urine and no DSM-5 diagnosis of CUD, 5. judged to be medically or psychiatrically unhealthy by study physicians at the time of screening, 6. ECG, read by a cardiologist, outside normal limits, 7. females not using an effective form of birth control or pregnant or breastfeeding, 8. contraindications or allergies to pentoxifylline, and 9. Self-reported history of head trauma, seizure, CNS tumors, or use of concomitant medications that lower seizure threshold, or first-degree family history of seizures.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.3 intervention groups are designated in this study
33.333% chance of being blinded to the placebo group
Treatment Groups
Group I
ExperimentalGroup II
ExperimentalGroup III
PlaceboStudy Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Psychopharmacology of Addiction Laboratory
Lexington, United StatesOpen Psychopharmacology of Addiction Laboratory in Google Maps